(Q38793230)

English

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.

scientific article published on 29 March 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1. (English)

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Joohee Sul

1

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

Gideon M Blumenthal

2

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

Xiaoping Jiang

3

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

Kun He

4

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

Patricia Keegan

5

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

Richard Pazdur

6

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

publication date

29 March 2016

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

21

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

5

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

643-650

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4861368

6 September 2017

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4861368

6 September 2017

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4861368

6 September 2017

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4861368

6 September 2017

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4861368

6 September 2017

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4861368

6 September 2017

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4861368

6 September 2017

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4861368

6 September 2017

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4861368

6 September 2017

Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4861368

14 September 2017

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4861368

31 August 2018

Identifiers

10.1634/THEONCOLOGIST.2015-0498

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

6 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38793230&oldid=1516757360"